ClinicalTrials.gg
Active, not recruitingNCT07612813Updated Oct 6, 2026

A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults

A Phase 1 interventional study of AZD7760 and Placebo in Staphylococcus Aureus Bloodstream Infection, sponsored by AstraZeneca. Active, not recruiting at 1 site in Japan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by AstraZeneca · Phase 1, Interventional, and Prevention

Updated Oct 6, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Sepsis with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Sepsis · Japan.

Enrollment
10th of 13
18 · median 203
Started
2026
with 1 other
Phase 1
2 of 17
none open now
Registered
17th of 17
by date
Lead sponsor
2 of 17
AstraZeneca

Among the 17 studies in Sepsis with a site in Japan, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 17th registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

1 of the 17 studies in Sepsis with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 319 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sepsis with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.

Read the detailed description

This is a Phase I, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety and PK of AZD7760, a mAb combination of suvratoxumab (labeled as MEDI4893) and AZD7745, in healthy Japanese adults. Two dosages of AZD7760 each administered as a single IV dose, will be assessed.

Study details include:

  • A Screening Period of up to 28 days.
  • A Dosing Period of 3 days, in which a single IV infusion will be given on Day 1.
  • A Follow-up Period of 12 months from the time of administration of the study intervention.
03

Conditions studied

  • Staphylococcus Aureus Bloodstream Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 45 kg and ≤ 110 kg and within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening.
  • Healthy Japanese participants with no concomitant diseases or medications.

Exclusion criteria

Exclusion Criteria:

  • Known to any component of the study intervention.
  • Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
  • bleeding disorder or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
  • or ALT above 1.5 × at screening.
  • Estimated \< 90 mL/min/1.73 m2.
  • or count below the lower limit of normal at screening.
  • White blood cell counts outside normal reference ranges.
  • History of other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
  • Any clinically significant abnormalities on 12-lead at screening,
  • Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on the day of planned dosing.
  • Known or suspected congenital or acquired immunodeficiency, or receipt of therapy.
  • Any condition that has the potential to increase clearance of the study intervention.
  • Blood donation or collection as follows:

    1. 400 mL whole blood donation within 12 weeks (males) or 16 weeks (females) prior to study drug administration.
    2. 200 mL whole blood donation within 4 weeks prior to study drug administration.
    3. Apheresis donation within 2 weeks prior to study drug administration.
  • Absence of suitable veins for blood sampling and administration of study intervention.
  • Any other condition that would compromise the safety of the participants.
  • Any condition that might interfere with evaluation of the study intervention or interpretation of participant safety or study results.
  • Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1 (AZD7760 Dose A)

    Participants receive an IV infusion of AZD7760 Dose A on Day 1.

    Drug: AZD7760

  • Experimental
    Cohort 2 (AZD7760 Dose B)

    Participants receive an IV infusion of AZD7760 Dose B on Day 1.

    Drug: AZD7760

  • Placebo comparator
    Pooled Placebo

    Participants receive an IV infusion of matching placebo on Day 1.

    Other: Placebo

Interventions

  • DrugAZD7760

    Participants will receive AZD7760 via IV infusion.

  • OtherPlacebo

    Participants will receive matching placebo via IV infusion.

06

What researchers measure

Primary outcomes

  1. Occurrence of Adverse Events (AEs)

    To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.

    Time frame: Day 1 to Day 181

  2. Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

Secondary outcomes

  1. Maximum observed serum (peak) drug concentration (Cmax)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  2. Time to reach peak or maximum observed concentration following drug administration (tmax)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  3. Terminal elimination half-life (t½λz)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  4. Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  5. Area under the concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  6. Volume of distribution at steady state (Vss)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  7. Volume of distribution based on the terminal phase (Vz)

    To characterize the PK of AZD7760 in serum of healthy Japanese adult participants.

    Time frame: Day 1 to Day 361

  8. Incidence of Anti-drug antibody (ADA)

    To evaluate ADA responses to AZD7760 in serum of healthy Japanese adult participants

    Time frame: Day 1 to Day 361

07

Study locations

1 site
  • Research Site
    Sumida-ku, 130-0004, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. ''Yes", indicates that AZ is accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 14 months after the start.

Of 32 phase 1 interventional studies under Sepsis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Sep 13, 2027
CompletionEst.
Sep 13, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612813
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 29, 2026
Primary completion
Sep 13, 2027 (estimated)
Completion
Sep 13, 2027 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion